“multiple-myeloma” Archives

Entry Author Date Location
All In One Place: A New Immuno-Oncology Trial Resource 10/19/16 National
Epic, Astronautics, Virent, & More: This Week’s Wisconsin Watchlist 09/19/16 Wisconsin
UW-Madison Awarded $12M NCI Grant to Study Cellectar Cancer Drug 09/14/16 Wisconsin
Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA 08/26/16 National
Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out 08/08/16 Boston
National Cancer Institute Awards Cellectar $2M For Clinical Study 08/05/16 Wisconsin
Agios, Celgene Jump into Immuno-Oncology in Revamped Alliance 05/17/16 Boston
Restructuring Looms for Forum as Neuro Drug Fails Key Clinical Test 03/24/16 Boston
Phoenix, Baird’s New CEO, & Epic’s Growth: This Week’s WI Watchlist 01/08/16 Wisconsin
East Coast Biotech Roundup: ASH, Kallyope, SQZ, Kyras & More 12/11/15 Boston
Shares in Cellectar Tumble After It Announces $3.3M Stock Offering 09/28/15 Wisconsin
Constellation Pharma Plots IPO Run As Genentech Passes on Buyout Deal 08/24/15 Boston
Celgene, Bluebird Streamline CAR-T Partnership To Fight Myeloma 06/03/15 Boston
ASCO Roundup: Checkpoints, Pushback Against Prices, CAR-T & More 06/02/15 National
East Coast Biotech Roundup: Hemophilia, Levin, Vertex, Semma & More 03/27/15 Boston
Tiger Teams, Dropping Subs, and Biotech’s Elusive Second Strikes 03/03/15 National
East Coast Biotech Roundup: Vertex, Syndax, Build-to-Buy Deals & More 02/20/15 Boston
West Coast Biotech Roundup: Qualcomm, Google X, Mapp, Onyx, & More 01/29/15 San Francisco
Officials Say Fuji’s Purchase of Kalon Boosts Texas’s Biotech Profile 12/22/14 Texas
After Spinning Onyx into Gold, Coles Returns to Lead a CNS Startup 12/15/14 Boston
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
Prescription Drug Pricing: The Fine Line Between Value and Greed 12/02/14 Boston
Wisconsin Roundup: VictorySpark, Imbed, Virent, Cellectar, & More 09/09/14 Wisconsin
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
Military Strategies Being Used in the War on Cancer 08/04/14 Seattle
How a Little Serendipity Led Acceleron to a Crippling Blood Disease 07/17/14 Boston
Amgen Agrees to Buy Onyx for $125 Per Share, or $10.4B 08/25/13 San Francisco
Celgene Partner Acceleron Files For IPO; Plans to Raise Up to $75M 08/07/13 Boston
Dunsire Out at Millennium as Takeda Reorganizes, Cuts Costs 05/09/13 Boston
Celgene Wins FDA Approval of Third Myeloma Drug 02/08/13 New York
Page 1 of 2 next page »